OncRef

Clinical Trial: NCT05756153

A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Genfleet Therapeutics (Shanghai) Inc.
Information Provided By:Genfleet Therapeutics (Shanghai) Inc.
Last Update Posted:2025-08-12

Study Overview

Brief Summary

This is a Phase Ib/II study. The objectives are to evaluate the safety/tolerability and efficacy of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC, to characterize pharmacokinetics (PK) of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC

Official Title

A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Conditions

Advance Non-small Cell Lung Cancer

Intervention / Treatment

  • Drug: GFH925
  • Drug: Cetuximab

Other Study ID Numbers

  • GFH925X0201

Start Date (Actual)

2023-04-25

Primary Completion Date (Actual)

2025-04-30

Study Completion Date (Actual)

2025-04-30

Enrollment (Actual)

47

Study Type

Interventional

Phase

Phase 1, Phase 2